Stock Rating Report for AFFY
|
|
Stock Information
| Ticker |
AFFY |
| Company Name |
Affymax, Inc |
| Current Price |
$10.65 |
| Previous Close |
$10.65 |
| Industry |
Biotechnology |
| Sector |
HEALTHCARE |
| Long Stop Loss |
Members Only |
| Short Stop Loss |
Members Only |
| Expected Move |
Members Only |
| Optionable? |
Yes
|
StockProphet Ratings
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Sector Risks
Chart
We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for AFFY. However, we only show it to our subscribers.
We update our ratings and stop losses EVERY WEEK.
Don't miss out on what we recommend for Affymax, Inc next week. Sign up today and start making money!
Demand Fundamentals
|
Demand Technicals
Company Profile
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to develop and commercialize Hematide. Affymax, Inc. was founded in 2001 and is based in Palo Alto, California.
|
Latest News
| Mon, 06 Feb 2012 14:42:47 GMT | 5 of Last Week's Biggest Winners | | Fri, 03 Feb 2012 20:01:06 GMT | The 9 Biotechs With The Highest Growth Expectations | | Thu, 02 Feb 2012 22:21:02 GMT | AFFYMAX INC Files SEC form 8-K, Change in Directors or Principal Officers | | Thu, 02 Feb 2012 21:13:38 GMT | Affymax promotes Smith to VP, market access, commercial development | | Thu, 02 Feb 2012 21:00:00 GMT | Affymax Promotes Cynthia Smith to Vice President, Market Access and Commercial Development | | Thu, 26 Jan 2012 21:34:51 GMT | Amgen Inc. Earnings: Increased Costs Strains Margins as Profit Drops | | Thu, 26 Jan 2012 18:13:58 GMT | Why There Won't Be A DNA Sequencing Land Grab | | Mon, 23 Jan 2012 16:10:24 GMT | Amgen Inc. Fourth Quarter Earnings Sneak Peek | | Fri, 20 Jan 2012 16:44:48 GMT | Nektar's drug diversity may be its strength | | Fri, 13 Jan 2012 19:12:15 GMT | Scenes, thoughts on the J.P. Morgan Healthcare Conference | | Thu, 12 Jan 2012 22:43:35 GMT | Stocks on the Road to Greatness | | Thu, 12 Jan 2012 01:00:17 GMT | Biggest Nasdaq Changes in Short Interest vs Float as of Dec. 30 | | Thu, 12 Jan 2012 01:00:13 GMT | Largest Nasdaq Short Interest Percent Decreases as of Dec. 30 | | Tue, 10 Jan 2012 21:05:30 GMT | 12 people to watch in Bay Area business 2012 | | Wed, 04 Jan 2012 22:15:00 GMT | Affymax to Webcast Analyst Briefing Event | | Wed, 04 Jan 2012 02:10:17 GMT | Another Entry in the Genome Patent Rumble | | Wed, 28 Dec 2011 20:15:55 GMT | Small-Cap, Biotech-Focused Hedge Fund BVF's Top Q3 Picks | | Tue, 27 Dec 2011 22:53:32 GMT | Largest Nasdaq Short Interest Percent Increases as of Dec. 15 | | Fri, 23 Dec 2011 19:30:00 GMT | [video] Friday 12/23 Insider Buying Report: VAC, AFFY | | Wed, 21 Dec 2011 16:15:59 GMT | Tuesday's Noteworthy Insider Buys And Sells | News provided by Yahoo! Finance |
|
|
|
|
